Acadia pharmaceuticals reports fourth quarter and full year 2023 financial results and operating overview

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad), today announced its financial results for the fourth quarter and full year ended december 31, 2023. “2023 was a transformational year for acadia that positioned us for continued success in 2024 and beyond. we achieved 40% revenue growth primarily driven by the launch of our second commercial product, daybue for the treatment of rett syndrome, in addition to 6% growth in our established nuplazid franchise,” said steve davis,.
ACAD Ratings Summary
ACAD Quant Ranking